MSD mulls 2025/26 launch for RSV vaccine after Phase II/III win
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
A Phase IIb/III trial with infants entering their first respiratory syncytial virus (RSV) season met its primary endpoints.
What's Your Reaction?
